What's in INSYS Therapeutics Inc's pipeline?

INSYS Therapeutics Inc has 11 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 9 in Phase 1.

Which companies overlap with INSYS Therapeutics Inc's portfolio?

Top competitors by shared drug class: , Alza Corporation, DE, USA, Cephalon.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/insys-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

INSYS Therapeutics Inc — Portfolio Competitive Intelligence Brief

INSYS Therapeutics Inc pipeline: 1 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 1 Phase 2 9 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Fentanyl sublingual spray	Fentanyl sublingual spray	marketed

Therapeutic area mix

Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Alza Corporation, DE, USA · 1 shared drug class
Cephalon · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for INSYS Therapeutics Inc:

Cite this brief

Drug Landscape (2026). INSYS Therapeutics Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/insys-therapeutics-inc. Accessed 2026-05-16.